Your email has been added to our waiting list and we will send an invite to you as soon as possible. Thank you for your patience.
In the meantime, if you happen to run a blog, our newly launched Blog Enhancement Suite can utilize the immense power of community to help you get more audience, engagement, content, and revenue with your own embeddable community! It will breathe new life into your blog and can automate many of the tedious tasks that come with the territory, so you can focus more on what matters most... writing.
Help spread the word about Snapzu:
Let others know about Snapzu by tweeting about us. We appreciate every mention!
The 12-month (M), phase 3, double-blind, randomised TRANSFORMS study demonstrated significant benefits of fingolimod 0.5 or 1.25 mg over interferon β-1a (IFNβ-1a) in patients with relapsing–remitting multiple sclerosis. We report the results of long-term (up to 4.5 years) extension of TRANSFORMS.